Log in to search using one of your social media accounts:

 

MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news

Inhibitors support immune therapy for leukemia
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from the German Cancer Consortium (DKTK) and the Munich University Hospital and T ü bingen University Hospital have shown that, in conjunction with certain inhibitors, this form of therapy could be successful in even more patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Mylotarg to treat acute myeloid leukemia
The U.S. Food and Drug Administration approved Mylotarg, or gemtuzumab, for the treatment of adults with newly diagnosed acute myloid leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 5, 2017 Category: Consumer Health News Source Type: news

Pfizer ’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment
The US Food and Drug Administration (FDA) has granted approval to Pfizer ’s antibody-drug conjugate (ADC) Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with acute myeloid leukaemia (AML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 3, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia
September 1, 2017 -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug
At lower dose, Mylotarg extended survival against a certain type of blood cancer Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 1, 2017 Category: Consumer Health News Source Type: news

Mylotarg Back on Market with New FDA Approval
(MedPage Today) -- Smaller doses OK'd for certain acute myeloid leukemia indications (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 1, 2017 Category: American Health Source Type: news

Mylotarg Approved for AML: Drug Returns to Market Mylotarg Approved for AML: Drug Returns to Market
After being voluntarily withdrawn 7 years ago, gemtuzumab ozogamicin (Mylotarg) is now returning to the market for the treatment of acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug, Mylotarg
FRIDAY, Sept. 1, 2017 -- The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia -- CD33-positive AML. An earlier version of the drug had been withdrawn... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 1, 2017 Category: General Medicine Source Type: news

FDA approves Pfizer's leukemia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML). (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
SILVER SPRING, Md., Sept. 1, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors expres... Biopharmaceuticals, Oncology, FDA Pfizer, Mylotarg, gemtuzumab ozogamicin, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 1, 2017 Category: American Health Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). (Source: World Pharma News)
Source: World Pharma News - September 1, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Medical News Today: Acute myeloid leukemia: Heart drugs may boost chemotherapy
Researchers find that drugs normally used to treat heart and blood vessel disease could also help to improve chemotherapy outcomes for patients with AML. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Astellas starts dosing gilteritinib patients in Phase III trial to treat AML
Astellas Pharma has started dosing patients with gilteritinib in a Phase III MORPHO clinical trial for the treatment of acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 22, 2017 Category: Pharmaceuticals Source Type: news

Vitamin C injections could play a role in treating blood cancers
Conclusion This mouse study explored whether treatment with vitamin C could restore function of TET2 and therefore block the progression of blood cancers like leukaemia. It found that using high doses of vitamin C intravenously did in fact suppress the growth of leukaemia cancer stem cells in the mice implanted with cell lines from human patients with leukaemia. It also reported that using vitamin C alongside existing treatment with PARP inhibitors helped reduce the progressions of the disease. The researchers suggest that in the future, vitamin C could be used alongside chemotherapy and other conventional treatment forms....
Source: NHS News Feed - August 21, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)
Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 17, 2017 Category: Pharmaceuticals Source Type: news

FDA grants orphan drug status to H3 Biomedicine ’s cancer treatment H3B-8800
H3 Biomedicine, a member of Eisai ’s global Oncology Business Group, has received orphan drug designation from the US Food and Drug Administration (FDA) for its H3B-8800, a clinical compound used to treat patients with acute myelogenous leukaemia (AML… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

Drug hope for acute myeloid leukemia
(University of Bradford) A new drug that strips cancer cells of their 'immortality' could help to treat patients suffering from one of the most aggressive forms of leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 8, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Jazz Pharmaceutical ’ s liposomal AML chemotherapy
Jazz Pharmaceuticals (NSDQ:JAZZ) said today that the FDA approved its Vyxeos injectable liposome for the treatment of adults with two types of acute myeloid leukemia. Vyxeos is the first product designed with the Dublin-based company’s CombiPlex technology, delivering a fixed-ratio of daunorubicin and cytarabine to a patient’s bone marrow. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves Jazz Pharmaceutical’s liposomal AML chemotherapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 7, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Oncology Pharmaceuticals Wall Street Beat jazzpharmaceuticals Source Type: news

D.C. Week: FDA User Fee Reauthorization Passes Congress
(MedPage Today) -- Also, FDA approves new treatments for acute myeloid leukemia (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 5, 2017 Category: American Health Source Type: news

FDA Approves Combination for Therapy-Related Acute Myeloid Leukemia
The FDA has approved a fixed combination of cytarabine and daunorubicin (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes. (Source: CancerNetwork)
Source: CancerNetwork - August 4, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Medical News Today: Leukemia breakthrough: Blood molecule key to treating AML
Heme, a chemical structure found in hemoglobin, is key to treating acute myeloid leukemia, an aggressive form of blood cancer, researchers have discovered. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 4, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

New Treatment Approved for Acute Myeloid Leukemia
Title: New Treatment Approved for Acute Myeloid LeukemiaCategory: Health NewsCreated: 8/3/2017 12:00:00 AMLast Editorial Review: 8/4/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 4, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves New Treatment for Acute Myeloid Leukemia
Vyxeos combines two previously approved drugs - - daunorubicin and cytarabine (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 4, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia
August 3, 2017 -- The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

Fixed Chemo Combo Vyxeos Approved for High-Risk AML Fixed Chemo Combo Vyxeos Approved for High-Risk AML
The fixed chemotherapy combination of daunorubicin and cytarabine, Vyxeos, has been approved for certain cases of high-risk acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

New Treatment Approved for Acute Myeloid Leukemia
Vyxeos combines two previously approved drugs (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 3, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Drug developer jazzed to receive FDA approval for leukemia treatment
Jazz Pharmaceuticals, a drug developer based in Ireland that is in the process of expanding its U.S. presence in Philadelphia, received Food and Drug Administration approval Thursday for its experimental leukemia treatment. The FDA approved Vyxeos as an injectable therapy for adults with two types of acute myeloid leukemia, a rapidly progressing and life-threatening blood cancer. Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals (Nasdaq: JAZZ), said Vyxeos is the first new chemotherapy advance… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 3, 2017 Category: Health Management Authors: John George Source Type: news

New Treatment Approved for Acute Myeloid Leukemia
Vyxeos combines two previously approved drugs Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 3, 2017 Category: Consumer Health News Source Type: news

FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia
The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 3, 2017 Category: American Health Source Type: news

New Combination Treatment, Vyxeos, Approved for Acute Myeloid Leukemia
THURSDAY, Aug. 3, 2017 -- The combination chemotherapy drug Vyxeos (daunorubicin and cytarabine) has been approved by the U.S. Food and Drug Administration as the first treatment for certain high-risk types of acute myeloid leukemia (AML). AML is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 3, 2017 Category: General Medicine Source Type: news

Discovery points to drugs that would 'short-circuit' deadly leukemia
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital scientists have found that cells of a deadly acute myeloid leukemia can be killed by blocking production of a molecular 'battery.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2017 Category: Cancer & Oncology Source Type: news

Helsinn and MEI Pharma begin dosing in Phase III combination trial for AML
Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase III clinical trial of pracinostat and azacitidine combination to treat adults with newly diagnosed acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 2, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Idhifa for Some With Acute Myeloid Leukemia
For adults with relapsed or refractory AML who have an IDH2 genetic mutation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 2, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Idhifa Approved for Some With Acute Myeloid Leukemia
Title: Idhifa Approved for Some With Acute Myeloid LeukemiaCategory: Health NewsCreated: 8/1/2017 12:00:00 AMLast Editorial Review: 8/2/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 2, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves New Targeted Agent for Acute Myeloid Leukemia
The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

FDA Approves Idhifa (enasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation
August 1, 2017 -- The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Idhifa to treat relapsed acute myeloid leukemia
The U.S. Food and Drug Administration today approved a new drug, Idhifa, to treat adults with relapsed or refractory acute myeloid leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 1, 2017 Category: Consumer Health News Source Type: news

Idhifa Approved for Some With Acute Myeloid Leukemia
For adults with specific genetic mutation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 1, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Idhifa Approved for Some with Acute Myeloid Leukemia
For adults with specific genetic mutation Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 1, 2017 Category: Consumer Health News Source Type: news

Cambridge's Agios wins FDA approval for first cancer drug
Cambridge-based Agios Pharmaceuticals has secured an early FDA approval for its first drug, a blood cancer treatment. The FDA on Tuesday announced the approval of enasidenib, a treatment for acute myeloid leukemia that will be sold under the brand name Idhifa. Celgene (Nasdaq: CELG) owns the rights to the drug under a previous agreement with Agios (Nasdaq: AGIO), under which the Cambridge company is eligible to r eceive royalties on net sales. Celgene submitted its application to the FDA just three… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 1, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

FDA approves leukemia treatment developed by Celgene, Agios
(Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia
The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 1, 2017 Category: American Health Source Type: news

Idhifa Approved for Some With Acute Myeloid Leukemia
TUESDAY, Aug. 1, 2017 -- Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML). The mutation in the IDH2... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 1, 2017 Category: General Medicine Source Type: news

Roche leukaemia drug gets FDA breakthrough therapy designation
ZURICH (Reuters) - Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia (AML) from the U.S. Food and Drug Administration, the Swiss drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants breakthrough therapy designation for Venclexta in acute myeloid leukaemia
Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Venclexta ® (venetoclax) in combination with low dose cytarabine (LDAC) for elderly patients with previously untreated AML who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 28, 2017 Category: Pharmaceuticals Source Type: news

Mum realises daughter's bruises were signs of rare cancer
Laura Handley, 29, from  Worcestershire, spotted the same marks James had on Tazmin, 1. Doctors diagnosed acute myeloid leukaemia (AML) a rare cancer which progresses rapidly. (Source: the Mail online | Health)
Source: the Mail online | Health - July 25, 2017 Category: Consumer Health News Source Type: news

Leukemia trial to match patients with drugs based on genetic biomarkers
The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational AML treatments. The non-profit said that three more unnamed biopharmaceutical companies are expected to join the effort soon. Get the full story at our sister site, Drug Delive...
Source: Mass Device - July 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Oncology Pharmaceuticals Wall Street Beat alexionpharmaceuticals Boehringer Ingelheim Pharmaceuticals Celgene Gilead Sciences Source Type: news

FDA Advisory Committee votes in favor of Pfizer's MYLOTARG (gemtuzumab ozogamicin) for acute myeloid leukemia
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk:benefit profile for MYLOTARG (gemtuzumab ozogamicin) 3 mg/m2 on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML). (Source: World Pharma News)
Source: World Pharma News - July 13, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news